ArticlePeerJ2021
Liver cancer mortality over six decades in an epidemic area: what we have learned.
Article in PeerJ, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Global diversities of disability caused by breast cancer in 204 countries and territories: a secondary analysis from global burden of disease study 2021.BMC public health · 2026Article
- Novel function of GTPBP2 in promoting hepatocellular carcinoma progression through inhibition of BTRC-mediated KRAS degradation.Cancer cell international · 2026Article
- Article
- Profound primary prevention of liver cancer following a natural experiment in China: A 50-year perspective and public health implications.International journal of cancer · 2025Article
- Fifty Years of Aflatoxin Research in Qidong, China: A Celebration of Team Science to Improve Public Health.Toxins · 2025Review
- Hepatitis B Virus Knowledge and HBV-Related Surveillance Status Among HBsAg-Positive Patients in Qidong City: A Rural-Based Cross-Sectional Survey.Healthcare (Basel, Switzerland) · 2024Article
- ADH4-a potential prognostic marker for hepatocellular carcinoma with possible immune-related implications.BMC cancer · 2024Article
- Frequencies and spectra of aflatoxin BNAR molecular medicine · 2024Article
- [Long-term trend analysis of liver cancer survival rate in Qidong region, Jiangsu Province, 1972-2019].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- A Bibliometric Analysis of the Role of 3D Technology in Liver Cancer Resection.World journal of surgery · 2023Review
- Survival of 48866 cancer patients: results from Nantong area, China.Frontiers in oncology · 2023Article
- [Analysis on the trend of liver cancer morbidity and mortality in certain district, Suzhou City, Jiangsu Province, 2017 to 2019].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- An Analysis of Microwave Ablation Parameters for Treatment of Liver Tumors from the 3D-IRCADb-01 Database.Biomedicines · 2022Article
- Global pattern of trends in incidence, mortality, and mortality-to-incidence ratio rates related to liver cancer, 1990-2019: a longitudinal analysis based on the global burden of disease study.BMC public health · 2022Article
- Analysis of the Curative Effect of Continuous Nursing Based on Data Mining on Patients with Liver Tumors.Computational and mathematical methods in medicine · 2022Article
- International comparison of trends in cancer mortality: Japan has fallen behind in screening-related cancers.Japanese journal of clinical oncology · 2021Article
- Liver Cancer Survival: A Real World Observation of 45 Years with 32,556 Cases.Journal of hepatocellular carcinoma · 2021Article
- Disease burden of liver cancer attributable to specific etiologies in China from 1990 to 2019: An age-period-cohort analysis.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsLiver cancer is one of the most dominant malignant tumors in the world. The trends of liver cancer mortality over the past six decades have been tracked in the epidemic region of Qidong, China. Using epidemiological tools, we explore the dynamic changes in age-standardized rates to characterize important aspects of liver cancer etiology and prevention.
methodsMortality data of liver cancer in Qidong from 1958 to 1971 (death retrospective survey) and from 1972 to 2017 (cancer registration) were tabulated for the crude rate (CR), and age-standardized rate and age-birth cohorts. The average annual percentage change was calculated by the Joinpoint Regression Program.
resultsThe natural death rate during 1958-2017 decreased from 9‰ to 5.4‰ and then increased to 8‰ as the population aged; cancer mortality rates rose continuously from 57/10
conclusionsThe crude mortality rate of liver cancer in Qidong has experienced trends from lower to higher levels, and from continued increase at a high plateau to most recently a gradual decline, and a change greatest in younger people. Many years of comprehensive prevention and intervention measures have influenced the decline of the liver cancer epidemic in this area. The reduction of intake levels of aflatoxin might be one of the most significant factors as evidenced by the dramatic decline of exposure biomarkers in this population during the past three decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.